Moleculin Biotech, Inc. (MBRX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.12 |
| Open | 2.7 |
| Day High | 2.82 |
| Day Low | 2.53 |
| 52-Week High | 24 |
| 52-Week Low | 1.79 |
| Volume | 11.19M |
| Average Volume | 194,541 |
| Market Cap | 14.67M |
| PE | -0.17 |
| EPS | -16.16 |
| Moving Average 50 Days | 2.52 |
| Moving Average 200 Days | 5.67 |
| Change | -0.37 |
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
GlobeNewswire Inc.
Mar 11, 2026 1:00 PM GMT
Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
GlobeNewswire Inc.
Feb 19, 2026 1:39 PM GMT
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain ou
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
GlobeNewswire Inc.
Feb 18, 2026 1:20 PM GMT
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter